Table 3.
Sig1R-dependent anti-seizure activity of allosteric Sig1R modulators.
| Compound | Dose, mg/kg | Seizure model | Effects | References |
|---|---|---|---|---|
| SKF83959 | 2 | Maximal electroshock seizure threshold test | No significant effect | Guo et al., 2015 |
| 10 | Increased the seizure threshold | |||
| 20 | ||||
| 40 | ||||
| 2 | PTZ (80 mg/kg, s.c.) |
No significant effect | ||
| 10 | No significant effect | |||
| 20 | Prolonged the latencies of clonic and generalized clonic-tonic seizures, survival time, and significantly lowered seizure scores | |||
| 40 | ||||
| 2 | Kainic acid (30 mg/kg, i.p.) |
No significant effect | ||
| 10 | No significant effect | |||
| 20 | No significant effect | |||
| 40 | Significantly reduced seizure incidence, prolonged the latency to seizures, and shortened the duration of seizures | |||
| SOMCL-668 | 40 | Maximal electroshock seizure threshold test | Increased the seizure threshold | Guo et al., 2015 |
| 40 | PTZ (80 mg/kg, s.c.) |
Prolonged the latency time to the generalized clonic-tonic seizures and survival time | ||
| 40 | Kainic acid (30 mg/kg, i.p.) |
Prolonged the latency time and shortened the duration of seizures | ||
| E1R | 10 | PTZ (i.v. infusion) |
Increased the threshold for clonic and tonic seizures | Vavers et al., 2017 |
| 50 | ||||
| 10 | BIC (i.v. infusion) |
No significant effect | ||
| 50 | Increased the threshold for clonic and tonic seizures | |||
| 75 | NE-100 (75 mg/kg, i.p.)* | Significantly reduced generalized seizure count and average behavioral score | ||
| Fenfluramine (ZX008) | Maximum Tolerable Concentration | Homozygous scn1a mutant zebrafish larvae | Decreased epileptiform activity | Sourbron et al., 2017 |
| 3 nmol | NMDA (i.c.v. administration) | Reduced rearing, hypermotility-circling, clonic convulsions, tonic seizures, and death | Rodríguez-Muñoz et al., 2018 | |
| 500 μM | Low Mg2+ | Blockade of early and late epileptiform activity | Gentsch et al., 2000 |